Although the overall prognosis for Australian patients with head and neck osteosarcoma is good, the role of chemotherapy and radiotherapy in this setting is unclear and more research is needed, Victorian researchers say.
A review of 15 patients attending the Royal Melbourne Hospital found that the overall 2, 5 and 15 year disease free survival rates were 92%, 74% and 74% respectively.
Increasing T stage and positive margins were found to significantly affect survival, the researchers found.
In line with previous research, their study did not find any strong association between histological subtype despite some suggestion that the chondroblastic variant has a better long-term outcome.
Adjuvant chemotherapy did not seem to affect survival positively and consequently, the most important factor for survival was adequate...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.